GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of its Herpes Zoster vaccine, Shingrix ...

Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

Shingrix [Herpes Zoster vaccine (recombinant, AS01 B ix adjuvanted)] is a non-live, recombinant subunit vaccine indicated for the prevention of shingles (herpes zoster) and, in some markets ...

Findings showed a noninferior immune response for both vaccines when Shingrix and Arexvy were coadministered compared with separate administration (primary endpoint). Both anti-gE antibody ...

PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...

The Advisory Committee on Immunization Practices (ACIP) recommends a single dose of zoster vaccine for immunocompetent adults 60 years of age and older, based on the results of this study ...

Among the 461,323 individuals who received at least 1 RZV dose, 1264 experienced new-onset gout within 60 days postvaccination; 302 patients were determined to have incident cases of gout, with no ...

The risk for incident gout following RZV exposure was not increased among adults aged 50 years or older, according to study findings.

Shingrix [Herpes Zoster vaccine (recombinant, AS01 B ix adjuvanted)] is a non-live, recombinant subunit vaccine indicated for the prevention of shingles (herpes zoster) and, in some markets, for ...